Optimizing regulatory T cells for therapeutic application in human organ transplantation

Trishan Vaikunthanathan; Niloufar Safinia; Giovanna Lombardi

doi:10.1097/MOT.0000000000000561

Optimizing regulatory T cells for therapeutic application in human organ transplantation

Trishan Vaikunthanathan, Niloufar Safinia, Giovanna Lombardi

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Initial clinical trials of adoptive regulatory T-cell (Treg) therapy in solid organ transplantation have proven to be both feasible and well tolerated. With Phase 2 trials underway, efforts have been focused on the optimization of the Treg product. RECENT FINDINGS: With science and our knowledge on the biology of these cells constantly advancing, we have been able to refine our search for a Treg population that would be ideally suited for therapeutic application. This idealized population must be readily isolated, allow for in-vitro expansion, demonstrate potent and specific suppressor function, maintain lineage stability and demonstrate a relevant homing profile. With the advent of innovative cell analysis/isolation techniques and genetic modifications, we are able to choose and design Tregs to fulfil these criteria. SUMMARY: By utilizing advances in science and technology, we can optimize Treg therapy in human organ transplantation maximizing their prospects in the arena of transplantation tolerance.

Original language	English
Pages (from-to)	516-523
Number of pages	8
Journal	Current Opinion in Organ Transplantation
Volume	23
Issue number	5
DOIs	https://doi.org/10.1097/MOT.0000000000000561
Publication status	Published - 1 Oct 2018

Access to Document

10.1097/MOT.0000000000000561

Cite this

@article{b1b09379da9c4e66923de7d0cd2db297,

title = "Optimizing regulatory T cells for therapeutic application in human organ transplantation",

abstract = "PURPOSE OF REVIEW: Initial clinical trials of adoptive regulatory T-cell (Treg) therapy in solid organ transplantation have proven to be both feasible and well tolerated. With Phase 2 trials underway, efforts have been focused on the optimization of the Treg product. RECENT FINDINGS: With science and our knowledge on the biology of these cells constantly advancing, we have been able to refine our search for a Treg population that would be ideally suited for therapeutic application. This idealized population must be readily isolated, allow for in-vitro expansion, demonstrate potent and specific suppressor function, maintain lineage stability and demonstrate a relevant homing profile. With the advent of innovative cell analysis/isolation techniques and genetic modifications, we are able to choose and design Tregs to fulfil these criteria. SUMMARY: By utilizing advances in science and technology, we can optimize Treg therapy in human organ transplantation maximizing their prospects in the arena of transplantation tolerance.",

author = "Trishan Vaikunthanathan and Niloufar Safinia and Giovanna Lombardi",

year = "2018",

month = oct,

day = "1",

doi = "10.1097/MOT.0000000000000561",

language = "English",

volume = "23",

pages = "516--523",

journal = "Current Opinion in Organ Transplantation",

issn = "1087-2418",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Optimizing regulatory T cells for therapeutic application in human organ transplantation

AU - Vaikunthanathan, Trishan

AU - Safinia, Niloufar

AU - Lombardi, Giovanna

PY - 2018/10/1

Y1 - 2018/10/1

N2 - PURPOSE OF REVIEW: Initial clinical trials of adoptive regulatory T-cell (Treg) therapy in solid organ transplantation have proven to be both feasible and well tolerated. With Phase 2 trials underway, efforts have been focused on the optimization of the Treg product. RECENT FINDINGS: With science and our knowledge on the biology of these cells constantly advancing, we have been able to refine our search for a Treg population that would be ideally suited for therapeutic application. This idealized population must be readily isolated, allow for in-vitro expansion, demonstrate potent and specific suppressor function, maintain lineage stability and demonstrate a relevant homing profile. With the advent of innovative cell analysis/isolation techniques and genetic modifications, we are able to choose and design Tregs to fulfil these criteria. SUMMARY: By utilizing advances in science and technology, we can optimize Treg therapy in human organ transplantation maximizing their prospects in the arena of transplantation tolerance.

AB - PURPOSE OF REVIEW: Initial clinical trials of adoptive regulatory T-cell (Treg) therapy in solid organ transplantation have proven to be both feasible and well tolerated. With Phase 2 trials underway, efforts have been focused on the optimization of the Treg product. RECENT FINDINGS: With science and our knowledge on the biology of these cells constantly advancing, we have been able to refine our search for a Treg population that would be ideally suited for therapeutic application. This idealized population must be readily isolated, allow for in-vitro expansion, demonstrate potent and specific suppressor function, maintain lineage stability and demonstrate a relevant homing profile. With the advent of innovative cell analysis/isolation techniques and genetic modifications, we are able to choose and design Tregs to fulfil these criteria. SUMMARY: By utilizing advances in science and technology, we can optimize Treg therapy in human organ transplantation maximizing their prospects in the arena of transplantation tolerance.

UR - http://www.scopus.com/inward/record.url?scp=85059348685&partnerID=8YFLogxK

U2 - 10.1097/MOT.0000000000000561

DO - 10.1097/MOT.0000000000000561

M3 - Article

C2 - 30024417

AN - SCOPUS:85059348685

SN - 1087-2418

VL - 23

SP - 516

EP - 523

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

IS - 5

ER -

Optimizing regulatory T cells for therapeutic application in human organ transplantation

Abstract

Access to Document

Other files and links

Fingerprint

Cite this